However, blocking tumor cell derived complement C3 enhanced antitumor functions by enhancing the efficacy of anti–PD-L1 treatment, suggesting C3 in combination with ICIs as a potential target for HCC therapy. This evidence concerns the gene C3 and neoplasm.